CN109890369B - 用于预防和减轻由糖尿病引起的慢性损伤的严重性的代谢调节剂和化合物的组合 - Google Patents

用于预防和减轻由糖尿病引起的慢性损伤的严重性的代谢调节剂和化合物的组合 Download PDF

Info

Publication number
CN109890369B
CN109890369B CN201780046806.6A CN201780046806A CN109890369B CN 109890369 B CN109890369 B CN 109890369B CN 201780046806 A CN201780046806 A CN 201780046806A CN 109890369 B CN109890369 B CN 109890369B
Authority
CN
China
Prior art keywords
formulation
diabetes
composition
effective
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780046806.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109890369A (zh
Inventor
奥拉西奥.阿斯图迪略德拉维嘉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57450744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109890369(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority claimed from PCT/MX2017/000061 external-priority patent/WO2017213486A2/es
Publication of CN109890369A publication Critical patent/CN109890369A/zh
Application granted granted Critical
Publication of CN109890369B publication Critical patent/CN109890369B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201780046806.6A 2015-06-08 2017-06-08 用于预防和减轻由糖尿病引起的慢性损伤的严重性的代谢调节剂和化合物的组合 Expired - Fee Related CN109890369B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562172339P 2015-06-08 2015-06-08
US15/176,422 US10285963B2 (en) 2015-06-08 2016-06-08 Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases
US15/176,422 2016-06-08
MXMX/A/2017/007448 2017-06-07
MX2017007448A MX365886B (es) 2015-06-08 2017-06-07 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas.
PCT/MX2017/000061 WO2017213486A2 (es) 2016-06-08 2017-06-08 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas

Publications (2)

Publication Number Publication Date
CN109890369A CN109890369A (zh) 2019-06-14
CN109890369B true CN109890369B (zh) 2022-04-29

Family

ID=57450744

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780046806.6A Expired - Fee Related CN109890369B (zh) 2015-06-08 2017-06-08 用于预防和减轻由糖尿病引起的慢性损伤的严重性的代谢调节剂和化合物的组合

Country Status (8)

Country Link
US (1) US10285963B2 (enExample)
JP (1) JP2019521184A (enExample)
CN (1) CN109890369B (enExample)
BR (1) BR112018075395A2 (enExample)
CA (1) CA3027048A1 (enExample)
ES (1) ES2988151T3 (enExample)
MX (1) MX365886B (enExample)
RU (1) RU2749950C2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017213486A2 (es) * 2016-06-08 2017-12-14 Astudillo De La Vega Horacio Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035612A2 (en) * 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
CN103889411A (zh) * 2011-07-15 2014-06-25 纽斯尔特科学公司 用于调节代谢途径的组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
US7709539B2 (en) * 2004-08-11 2010-05-04 Chang Gung University Therapeutic use of resveratrol for hyperglycemia
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
US20080286254A1 (en) * 2007-05-17 2008-11-20 Kaneka Corporation Composition comprising licorice polyphenol
JP5594819B2 (ja) * 2009-12-22 2014-09-24 キリンホールディングス株式会社 脂質代謝改善用組成物
JP2012041296A (ja) * 2010-08-19 2012-03-01 Medience Corp 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035612A2 (en) * 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
CN103889411A (zh) * 2011-07-15 2014-06-25 纽斯尔特科学公司 用于调节代谢途径的组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α;Marie Lagouge et al;《Cell》;20061116;第127卷;第1109-1122页 *

Also Published As

Publication number Publication date
MX365886B (es) 2019-06-19
RU2749950C2 (ru) 2021-06-21
US20160354331A1 (en) 2016-12-08
US10285963B2 (en) 2019-05-14
RU2018147077A3 (enExample) 2020-09-21
JP2019521184A (ja) 2019-07-25
RU2018147077A (ru) 2020-07-10
MX2017007448A (es) 2018-09-10
CN109890369A (zh) 2019-06-14
ES2988151T3 (es) 2024-11-19
CA3027048A1 (en) 2017-12-14
BR112018075395A2 (pt) 2019-04-02

Similar Documents

Publication Publication Date Title
Ali et al. Apitherapy for age-related skeletal muscle dysfunction (sarcopenia): A review on the effects of royal jelly, propolis, and bee pollen
Ali et al. Royal jelly as an intelligent anti-aging agent—A focus on cognitive aging and Alzheimer’s disease: A review
Takikawa et al. Dietary anthocyanin-rich bilberry extract ameliorates hyperglycemia and insulin sensitivity via activation of AMP-activated protein kinase in diabetic mice
Vinayagamoorthi et al. Antioxidants preserve redox balance and inhibit c-Jun-N-terminal kinase pathway while improving insulin signaling in fat-fed rats: evidence for the role of oxidative stress on IRS-1 serine phosphorylation and insulin resistance
Nasseri et al. Benefits of curcumin supplementation on antioxidant status in β-thalassemia major patients: a double-blind randomized controlled clinical trial
Talagavadi et al. Cyanidin-3-O-β-glucoside and protocatechuic acid activate AMPK/mTOR/S6K pathway and improve glucose homeostasis in mice
CA2917712C (en) Compositions prepared from poultry and methods of their use
He et al. Oral L-theanine administration promotes fat browning and prevents obesity in mice fed high-fat diet associated with the modulation of gut microbiota
KR20190080877A (ko) 유기 셀레늄 화합물 함유 조성물
US10058579B2 (en) Dietary supplements containing extracts of cinnamon and methods of using same to promote enhanced sirtuin, cell and telomere integrity
Niewiadomska et al. Effects of Punica granatum L. peel extract supplementation on body weight, cardiac function, and haematological and biochemical parameters in an animal model of metabolic syndrome
US10285963B2 (en) Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases
EP3470060B1 (en) Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome
HK40010029A (en) Combination of metabolic regulators and compounds for preventing and reducing the severity of chronic damage caused by diabetes
HK40010029B (en) Combination of metabolic regulators and compounds for preventing and reducing the severity of chronic damage caused by diabetes
KR20080019242A (ko) 글루코스 대사부전 치료용 약제
OA19128A (en) Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes.
Vučević et al. Methionine-choline deprivation alters liver and brain acetylcholinesterase activity in C57BL6 mice
Li et al. Prevention of Obesity-Induced Nonalcoholic Fatty Liver Disease Using Grape Pomace Extract.
Thaipitakwong Efficacy and safety of mulberry leaves on glycemic control in patients with obesity and patients with type 2 diabetes
Tabęcka-Łonczyńska et al. Impact of Hericium erinaceus and Ganoderma lucidum metabolites on AhR activation in neuronal HT-22 cells
Turska et al. A review of the health benefits of food enriched with kynurenic acid. Nutrients. 2022; 14: 4182
Okunishi et al. Assessment of mutagenicity, acute and sub-acute toxicity and human trial safety of wasabi leaf extract powder
Rodrigues The impact of blackberry supplementation on skeletal muscle mitochondrial dynamics in a humanized mouse model of obesity
Nakayama Anti-inflammatory, Antioxidant, and Anti-apoptotic Effects of Carnitine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40010029

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220429

CF01 Termination of patent right due to non-payment of annual fee